Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 2/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40410 | 0.82 | MAPT (0.41) | MAPTESR1ESR2MGAMCA4 | |
| SCHEMBL40408 | 0.76 | MAPT (0.40) | MAPTESR1ESR2MGAMNR1H2 | |
| SCHEMBL11316383 | 0.74 | MAPT (0.39) | MAPTESR1ESR2MGAMNR1H2 | |
| SCHEMBL869282 | 0.74 | MAPT (0.39) | MAPTESR1ESR2MGAMNR1H2 | |
| SCHEMBL2355439 | 0.72 | MAPT (0.42) | MAPTESR1ESR2MGAMNR1H2 | |
| SCHEMBL1470884 | 0.72 | MAPT (0.38) | MAPTESR1ESR2MGAMNR1H2 | |
| SCHEMBL16325251 | 0.72 | MAPT (0.38) | MAPTESR1ESR2MGAMNR1H2 | |
| SCHEMBL7033371 | 0.72 | MAPT (0.42) | MAPTESR1ESR2MGAMNR1H2 | |
| SCHEMBL11316112 | 0.71 | MAPT (0.41) | MAPTESR1ESR2MGAMNR1H2 | |
| SCHEMBL9217667 | 0.71 | MAPT (0.47) | MAPTESR1ESR2MGAMNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111330016-A | Antibody Drug Conjugates (ADC) that bind to 158P1D7 protein | 艾更斯司股份有限公司 | 2020-06-26 | — | — | CN | disclosed |
| CN-111330017-A | Antibody Drug Conjugates (ADC) that bind to 158P1D7 protein | 艾更斯司股份有限公司 | 2020-06-26 | — | — | CN | disclosed |
| CN-105073132-B | Antibody Drug Conjugates (ADC) that bind to 158P1D7 protein | 艾更斯司股份有限公司 | 2020-01-10 | — | — | CN | disclosed |
| EP-2560634-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | Piramal Enterprises Limited (IN) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011132171-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | WO | disclosed |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | US | disclosed |
| EP-1896480-A1 | CRIPOWELLINS AND SYNTHETIC DERIVATIVES THEREOF USED AS MEDICAMENTS | Bayer CropScience Aktiengesellschaft (DE) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006136309-A1 | CRIPOWELLINS AND SYNTHETIC DERIVATIVES THEREOF USED AS MEDICAMENTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | NOS2, NOS1, NOS3 | MAPT 4304/4885ESR1 1694/4885ESR2 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.